Welcome!

News Feed Item

Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2014-2024

LONDON, Feb. 17, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2014-2024

Report Details

Needle-free injecting technologies - discover activities, developments, and prospects of leading companies

What does the future hold for makers of needle-free injection (NFI) products? See what's possible. Visiongain's updated report shows you data to 2024 for that industry and market. There you find analysis, trends, opportunities, and forecasting of revenues.

Our study analyses 14 leading developers and producers of those medical devices. You can now explore the future of NFI to introduce drugs, finding its potential. Discover how you can benefit.

Forecasts and other data for staying ahead in knowledge of those medical injectors

There you examine the industry for needleless injection and needle-free syringes - insulin injectors and other systems. Find what's happening. Potential exists for novel and improved subcutaneous, intradermal, intramuscular, and intravenous drug delivery.

That industry advances. In our report you assess product ranges, historical data, R&D, market shares, sales predictions, and growth rates. There you get quantitative and qualitative analyses. You also find 42 tables, 17 charts and three research interviews.

NFI technology - discover how to help your work, also finding where money lies

Avoid missing out. See how developers overcome problems with parenteral drug application, esp. benefiting use of biological drugs (biologics). You also discover potential revenues.

So the following sections outline what you get in our investigation.

Companies based in North America - what're their outlooks?

First our study gives you financial data and discussions for prominent North American NFI developers and manufacturers:
• Antares Pharma
• Bioject Medical Technologies
• Zogenix
• Activa
• D'Antonio Consultants International.

You also find profiles of these organisations:
• National Medical Products
• Medical International Technologies
• Penjet Corporation
• PharmaJet
• Valeritas.

Discover what the present and future hold for those companies. Also find the money. See revenue predictions to 2024 for the overall world industry for needle-free injection devices.

Hear, too, about developments and prospects of competitors in other countries.

Europe - outlooks for leading developers and producers of medical injection technology

Next our report analyses European-based specialists in that drug delivery:
• Akra Dermojet
• Crossject Medical Technology
• Injex Pharma
• Glide Pharma.

Many commercial opportunities exist, with expanding revenues possible this decade. Discover the best potentials. You find how companies gain advantages and raise sales.

In that work you see what affects the future - what influences success.

Events and forces for developing, producing, marketing, and selling NFI technologies

Our study explains issues affecting that industry and market from 2013 onwards, including these:
• Applications - pain management, vaccine delivery, treating diabetes, paediatric medicine, and other therapies
• Regulations in the US and Europe
• Developments stimulating and restraining that market, inc. allied and competing products.

You also investigate these forces:
• Jet injector devices, transdermal patches, microneedles, pen injectors, and other therapeutic systems
• Solid formulations and other challenges, innovations, and progress in therapy
• Deals, collaborations, and other changes affecting that sector.

There you explore political, economic, social, and technological questions, investigating outlooks for business. Examine what stimulates and restrains that industry and market.

You discover, then, what the present and future hold. You also read opinions from our survey of companies. Stay ahead for information.

Ways Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2014-2024 helps you

In particular, our report gives you the following knowledge:
• Profiles of 14 leading companies - assess products, strategies, and results
• Competition and opportunities - explore what affects the needle-free injectors industry, finding what influences its sales and determines its future
• Revenues to 2024 for that market at world level - discover prospects for success.

That work helps people interested in the future of pharmaceuticals and related instruments, containers, and accessories.

Analysis found nowhere else - discover the future of those devices and applications

Our work gives independent analysis. There you receive business intelligence found only in our report. You're free to choose, and our work lets you discover where the money lies.

With that investigation you're less likely to fall behind in information or miss opportunity. See there how you could benefit your research, analysis, and decisions. So avoid missing out.

Also find how you could save time and get recognition for insight, raising your influence.

1. Executive Summary

1.1 Leading NFI Device Manufacturers: Overview of Findings
1.2 Chapters in the Report
1.3 Research and Analysis Methods
1.4 Aims, Scope and Format of the Report
1.5 Glossary of Terms

2. Introduction to Needle-Free Injection

2.1 What is Needle-Free Drug Delivery?
2.1.1 History of Needle-Free Injections: From Military to Clinic
2.1.2 Modern Needle-Free Devices: Concept of High Pressure Fluid Jet
2.2 What is the Rationale for Needle-Free Injections?
2.3 Applications of Needle-Free Drug Delivery
2.3.1 Pain Management: Using NFI Devices to Administer Lidocaine
2.3.2 Vaccine Delivery: Improving Immune Response
2.3.3 Insulin Delivery: Jet Injection Enhances Drug Distribution
2.3.4 Paediatrics: Alleviating Childhood Anxiety and Phobia
2.4 Regulation of Needle-Free Delivery Devices
2.4.1 The US Regulation System: Prolonged Approval Process
2.4.2 The European Regulation System: Manufacturers Seeking EU Approval First?
2.5 Advantages and Disadvantages of Needle-Free Systems

3. The Global Needle-Free Injection Device Market, 2013-2024

3.1 The Global Needle-Free Injection Device Market, 2012
3.2 The Global Needle-Free Injection Device Market: Revenue Forecast, 2013-2024
3.3 How Will the Market Shares of Leading Sectors Change From 2013-2024?
3.4 What Will Drive the Global Needle-Free Injection Device Market Between 2014 and 2024?
3.5 What Factors are Likely to Restrain the Global Needle-Free Injection Device Market Between 2014 and 2024?
3.6 The Global Jet Injector Device Market, 2012
3.6.1 The Global Jet Injector Device Market: Revenue Forecast, 2013-2024
3.6.2 The Global Jet Injector Device Market: Industry Trends, 2013-2024
3.7 The Global Competing Technologies Market, 2012
3.7.1 The Global Competing Technologies Market: Revenue Forecast, 2013-2024
3.7.2 The Global Competing Technologies Market: Industry Trends, 2013-2024
3.7.2.1 Transdermal Patches: Attractive and Cheap Option
3.7.2.2 Microneedle Technology: Huge Potential for Mass Vaccinations
3.7.2.3 Metered Dose Inhalers: Change in Device Propellant to Drive Adoption

4. The Leading North American Needle-Free Injection Device Manufacturers, 2013

4.1 Antares Pharma
4.1.1 Needle-Free Products
4.1.1.1 Vision™: Delivering Liquid Insulin or Human Growth Hormone
4.1.1.2 Vibex™: Hidden Needle to Alleviate Patient Fear
4.1.1.3 Pen Injector: Devices Being Used Clinical Testing
4.1.2 Sales Performance, 2012
4.1.3 Needle-Free Injection Device Pipeline
4.1.3.1 Vibex™ MTX: Targeting Growing Population of RA Sufferers
4.1.3.2 Vibex™ QS (QuickShot): Modified Vibex to Offer Improved Function
4.1.3.3 OTREXUP™: Combining Vibex MTX and Methotrexate
4.2 Bioject Medical Technologies
4.2.1 Needle-Free Products
4.2.1.1 Biojector® 2000: Adaptable Power Source Allows Use in Home and Mass Vaccination Setting
4.2.1.2 Vitajet™: Low-cost Insulin Delivery System
4.2.1.3 ZetaJet™: Auto-disable Feature Improves User Safety
4.2.2 Sales Performance
4.2.3 Needle-Free Injection Device Pipeline
4.2.3.1 Intradermal Pen Injector: Targeted Drug Delivery
4.2.3.2 Iject®: Providing Tailored Depth of Penetration
4.2.3.3 Jupiter Jet: Multi Dosing With Single Loaded Syringe
4.2.4 Collaborations
4.2.4.1 MPI Research: Seeking Drug/Device Combinations
4.2.4.2 World Health Organisation (WHO): the Push to Eradicate Infectious Disease in Developing Countries
4.3 Zogenix
4.3.1 Needle-Free Products
4.3.1.1 Sumavel® DosePro®: Rapid Acting Migraine Relief
4.3.2 Sales Performance, 2012
4.3.3 Needle-Free Injection Device Pipeline
4.3.3.1 Relday™: Needle-based Alterative for Improved Drug Distribution
4.3.4 Collaborations
4.3.5 Manufacturing
4.4 Activa Brand Products, Inc.
4.4.1 Technology: the Activa Family for Diabetics
4.4.2 Needle-Free Products
4.4.2.1 Product Advantages
4.5 D'Antonio Consultants International Inc. (DCI)
4.5.1 Needle-Free Products
4.5.1.1 LectraJet®: Lightweight Device Reduces User Fatigue
4.5.2 Needle-Free Injection Device Pipeline
4.5.2.1 Low Workload Jet Injector: Single-shot Manuel System
4.5.2.2 Multi Channel Jet Injector: For Simultaneous Vaccine Delivery
4.6 National Medical Products, Inc.
4.6.1 Needle-Free Products
4.6.1.1 J-Tip®: Offering Needle-free Administration of Anaesthesia
4.7 Medical International Technologies
4.7.1 Needle-Free Products
4.7.1.1 MED-JET®: Extremely Thin Orifice Offers Improved Drug Absorption
4.7.2 Sales Performance, 2012
4.7.3 Increased Awareness Through Globalisation
4.8 Penjet Corporation
4.8.1 Needle-Free Products
4.8.1.1 Penjet®: Nitrogen-powered Device Allows Efficient Storage
4.8.2 Applications
4.8.2.1 Multi-Component Drugs
4.8.2.2 Lyophilised Drug Delivery
4.8.2.3 Small Pox Vaccination
4.9 PharmaJet
4.9.1 Needle-Free Products
4.9.1.1 STRATIS®: Drug Delivery in Less Than a Second
4.9.2 Applications
4.9.3 Collaborations: Pursuing a Drug/Device Combination for Vaccine Administration
4.10 Valeritas
4.10.1 Needle-Free Products
4.10.1.1 Mini-Ject™: Potential Delivery of Lyophilised Drugs May Open Huge Opportunities for Valeritas

5. The Leading European Needle-Free Injection Device Manufacturers, 2013

5.1 Akra Dermojet
5.1.1 Needle-Free Products
5.1.1.1 Dermojet® "HR": User-Friendly Design Allows Use in High Intensive Applications
5.1.1.2 DERMOJET Polymedical®: Interchangeable Injection Tips Reduces Risk of Contamination
5.1.1.3 Automatic DERMOJET®
5.2 Crossject Medical Technology
5.2.1 Technology: Highly Customisable Device Allows Tailoring to Specific Drugs
5.2.2 Needle-Free Products
5.2.2.1 Zeneo®: Gas Propellant Generated Upon Injection
5.3 Injex Pharma AG
5.3.1 Needle-Free Products
5.3.1.1 INJEX30®: First Multiple Application Needle-Free Device?
5.4 Glide Pharma
5.4.1 Needle-Free Products
5.4.1.1 Glide SDI®
5.4.1.2 Applications
5.4.2 Advantages
5.4.2.1 Injecting Solid Formulations
5.4.2.2 Pharmaceutical Companies
5.4.3 Collaboration with Pfenex Inc. To Aid Delivery of Solid Dose Vaccine

6. Qualitative Analysis of the Global Needle-Free Injection Device Market, 2013-2024

6.1 SWOT Analysis of the Global Needle-Free Injection Device Market, 2013-2024
6.1.1 Strengths
6.1.1.1 A Less Painful Alternative to Needle-Based Injections
6.1.1.2 No Specialist Training Required for Delivery
6.1.1.3 Reduced Transport Costs
6.1.2 Weaknesses
6.1.2.1 Expensive Technology
6.1.2.2 Inefficient Manufacturing Process
6.1.2.3 Off Patent/Generics Require Reformulating Prior to Use in Needle-Free Delivery Systems
6.1.3 Opportunities
6.1.3.1 Emerging Economies
6.1.3.2 Mass Immunisation Programmes
6.1.3.3 Potential Delivery of Vaccines
6.1.3.4 Patent Expiry of Leading Drugs will Increase Competition
6.1.4 Threats
6.1.4.1 Traditional Needles and Syringes are Cheap to Mass Produce
6.1.4.2 Limited Clinical Data
6.1.4.3 Increased Scrutiny from Regulatory Bodies
6.1.4.4 Medical Device Excise Tax
6.2 STEP Analysis of the Global Needle-Free Injection Device Market, 2013-2024
6.2.1 Social Factors
6.2.2 Technological Developments
6.2.3 Economical Pressures
6.2.4 Political Issues

7. Opinions from Our Industry Survey

7.1 Interview with Zogenix Technologies
7.1.1 Recent Technological Developments in Needle-Free Systems
7.1.2 Competing Technologies and Market Opportunities
7.1.3 Market Restraints and Future Directions
7.2 Interview with Bioject Medical Technologies
7.2.1 Finding a Competitive Edge over Market Rivals
7.2.2 Market Dynamics and Company Collaborations
7.2.3 Potential of Emerging Markets and Regulatory Concerns
7.3 Interview with Team Consulting
7.3.1 Historical Development of the Needle-Free Market
7.3.2 Company Activities and Overcoming the Skin Barrier
7.3.3 Challenges and Limits to Market Growth
7.3.4 Prospects for the Needle-Free Market

8. Conclusions

8.1 The Global Needle-Free Injection Device Market, 2013-2024
8.2 Zogenix Dominated the Global Needle-Free Injection Device Market in 2012
8.3 Strong Company Pipeline Will Help Drive the Market
8.4 Concluding Remarks

List of Tables

Table 1.1 Currency Exchange Rates
Table 2.1 Examples of Needle-Free Vaccine Delivery Systems, 2013
Table 2.2 Examples of Needle-Free Insulin Delivery Systems, 2013
Table 2.3 Advantages and Disadvantages of Needle-Free Injection, 2013
Table 3.1 The Global Needle Free Injection Device Market: Revenue ($m) and Market Share (%) by Technology, 2012
Table 3.2 The Global Needle-Free Injection Device Market: Revenue Forecast ($m, AGR %, CAGR %) by Technology, 2013-2024
Table 3.3 The Global Needle-Free Injection Device Market: Market Share (%) by Technology, 2013-2024
Table 3.4 The Global Needle-Free Injection Device Market: Drivers and Restraints, 2013-2024
Table 3.5 Patent Expiries for Leading Drugs, 2014-2016
Table 3.6 Classification of Jet Injector Devices, 2013
Table 3.7 The Global Jet Injection Device Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.8 The Global Competing Needle-Free Technologies Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.9 Insulin Inhalation Systems in Development, 2013
Table 3.10 Vaccine Inhalers in Development, 2013
Table 4.1 Antares Pharma: Key Facts, 2013
Table 4.2 Antares Pharma Licensing Partnerships, 2013
Table 4.3 Antares Pharma: Revenue ($m) & Revenue Share (%) by Business Segment, 2012
Table 4.4 Antares Pharma: Product Revenue ($m, CAGR %) by Category, 2010-2012
Table 4.5 Bioject Medical Technologies: Key Facts, 2013
Table 4.6 Bioject: Revenue ($m) and Revenue Share (%), by Product Line, 2010
Table 4.7 Bioject: Summary of Technologies
Table 4.8 Zogenix: Key Facts, 2013
Table 4.9 Zogenix: Summary of Technology
Table 4.10 Zogenix: Revenue ($m) and Revenue Share (%) by Business Segment, 2012
Table 4.11 Activa Brand Products: Key Facts, 2013
Table 4.12 D'Antonio Consultants: Key Facts, 2013
Table 4.13 National Medical Products: Key Facts, 2013
Table 4.14 Medical International Technologies: Key Facts, 2013
Table 4.15 Medical International Technologies: Revenue ($m, CAGR %), 2009-2012
Table 4.16 PenJet Corporation: Key Facts, 2013
Table 4.17 PharmaJet: Key Facts, 2013
Table 4.18 Valeritas: Key Facts, 2013
Table 5.1 Akra Dermojet: Key Facts, 2013
Table 5.2 Akra Dermojet: Summary of Technology
Table 5.3 Crossject Medical Technology: Key Facts, 2013
Table 5.4 Injex Pharma AG: Key Facts, 2013
Table 5.5 Glide Pharma: Key Facts, 2013
Table 6.1 SWOT Analysis of the Global Needle-Free Injection Device Market, 2013-2024
Table 6.2 Average Price for Needle-Free Drug/Vaccine Delivery Technology, 2013
Table 6.3 Patent Expiries for Leading Drugs, 2014-2016
Table 6.4 The Global Needle-Free Injection Market: STEP Analysis, 2013-2024
Table 8.1 The Global Needle-Free Injection Device Market: Revenue Forecast ($m, AGR %, CAGR %) and Market Share (%) by Technology, 2012, 2015, 2018, 2021 and 2024

List of Figures

Figure 3.1 The Global Needle Free Injection Device Market: Share (%) by Technology, 2012
Figure 3.2 The Global Needle Free Injection Device Market: Revenue ($m) by Technology, 2012
Figure 3.3 The Global Needle-Free Injection Device Market: Revenue Forecast ($m), 2013-2024
Figure 3.4 The Global Needle-Free Injection Device Market: Share (%) by Technology, 2018
Figure 3.5 The Global Needle-Free Injection Device Market: Share (%) by Technology, 2024
Figure 3.6 The Global Jet Injection Device Market: Revenue Forecast ($m), 2013-2024
Figure 3.7 The Global Competing Needle-Free Technologies Market: Revenue Forecast ($m), 2013-2024
Figure 4.1 Antares Pharma: Revenue Share (%) by Business Segment, 2012
Figure 4.2 Antares Pharma: Product Revenue ($m) by Category, 2010-2012
Figure 4.3 Bioject: Revenue Share (%) by Product Line, 2010
Figure 4.4 Bioject: Revenue ($m), 2010-2012
Figure 4.5 Zogenix: Revenue Share (%) by Business Segment, 2012
Figure 4.6 Zogenix: Revenue ($m) by Business Segment, 2010-2012
Figure 4.7 Medical International Technologies: Revenue ($m), 2009-2012
Figure 6.1 The Transport Process for a Vaccine
Figure 8.1 The Global Needle-Free Injection Device Market: Revenue Forecast ($m) by Technology, 2012, 2015, 2018, 2021 and 2024
Figure 8.2 The Global Needle-Free Injection Device Market: Leading Companies by Revenue ($m), 2012

Companies Listed

3M
Actavis
Activa Brand Products
Aerogen
Akra Dermojet
ALZA Pharmaceuticals
Ankara University
Antares Pharma
Aradigm Corporation
Astellas Pharma
AstraZeneca
Battelle
Bill and Melinda Gates Foundation
Bioject Medical Technologies
BioValve Technologies
Bristol-Myers Squibb
Cambridge Consultants
CDC Measles Eradication Committee
Centre for Devices and Radiological Health (CDRH)
Centre for Disease Control and Prevention (CDC)
China State Food and Drug Administration (SFDA)
Covidien
Crossject Medical Technology
CSL Behring
CSL Limited
Daewoong Pharmaceuticals
Dance Pharmaceuticals
D'Antonio Consultants International
Diabetes Management International
Dr. Reddy's Laboratories
Durect Corporation
Echo Therapeutics
Eli Lilly
Eurojet Medical
European Union
Ferndale Pharma Group
Ferring Pharmaceuticals
Food and Drug Administration (FDA)
Georgia Tech University
GlaxoSmithKline (GSK)
Glide Pharma
Harvard University
Injex Pharma AG
JCR Pharmaceuticals
Jiangsu Hualan Medical International Technologies
Johnson & Johnson
Mallinckrodt Pharmaceuticals
MannKind
Meda Pharmaceuticals
Medical International Technologies
MedImmune
Merck & Co.
Merck Serono
Mglas AG
Minnesota Rubber and Plastics (MRP)
MPI Research
Mylan
National Medical Products
Nektar Therapeutics
North Carolina University
Novartis
Novo Nordisk
Nypro Limited
Patheon
Penjet Corporation
Pfenex Inc.
Pfizer
PharmaJet
Philips Medical
Sanofi-Aventis
Sanofi-Pasteur
Takeda
Team Consulting
Teva Pharmaceuticals
UCB
University of Colorado
US Army Medical Research Institute of Infectious Disease (USAMRIID)
Valeritas
Vaxxas
Weston Medical
World Health Organization (WHO)
Zogenix
Zomajet
Zosano Pharma

Read the full report:
Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2014-2024
http://www.reportbuyer.com/pharma_healthcare/medical_devices/medical_device_leader_series_top_needle_free_injection_device_manufacturers.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Blockchain. A day doesn’t seem to go by without seeing articles and discussions about the technology. According to PwC executive Seamus Cushley, approximately $1.4B has been invested in blockchain just last year. In Gartner’s recent hype cycle for emerging technologies, blockchain is approaching the peak. It is considered by Gartner as one of the ‘Key platform-enabling technologies to track.’ While there is a lot of ‘hype vs reality’ discussions going on, there is no arguing that blockchain is b...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settle...
"IBM is really all in on blockchain. We take a look at sort of the history of blockchain ledger technologies. It started out with bitcoin, Ethereum, and IBM evaluated these particular blockchain technologies and found they were anonymous and permissionless and that many companies were looking for permissioned blockchain," stated René Bostic, Technical VP of the IBM Cloud Unit in North America, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Conventi...
A strange thing is happening along the way to the Internet of Things, namely far too many devices to work with and manage. It has become clear that we'll need much higher efficiency user experiences that can allow us to more easily and scalably work with the thousands of devices that will soon be in each of our lives. Enter the conversational interface revolution, combining bots we can literally talk with, gesture to, and even direct with our thoughts, with embedded artificial intelligence, whic...
The cloud era has reached the stage where it is no longer a question of whether a company should migrate, but when. Enterprises have embraced the outsourcing of where their various applications are stored and who manages them, saving significant investment along the way. Plus, the cloud has become a defining competitive edge. Companies that fail to successfully adapt risk failure. The media, of course, continues to extol the virtues of the cloud, including how easy it is to get there. Migrating...
The need for greater agility and scalability necessitated the digital transformation in the form of following equation: monolithic to microservices to serverless architecture (FaaS). To keep up with the cut-throat competition, the organisations need to update their technology stack to make software development their differentiating factor. Thus microservices architecture emerged as a potential method to provide development teams with greater flexibility and other advantages, such as the abili...
ChatOps is an emerging topic that has led to the wide availability of integrations between group chat and various other tools/platforms. Currently, HipChat is an extremely powerful collaboration platform due to the various ChatOps integrations that are available. However, DevOps automation can involve orchestration and complex workflows. In his session at @DevOpsSummit at 20th Cloud Expo, Himanshu Chhetri, CTO at Addteq, will cover practical examples and use cases such as self-provisioning infra...
Product connectivity goes hand and hand these days with increased use of personal data. New IoT devices are becoming more personalized than ever before. In his session at 22nd Cloud Expo | DXWorld Expo, Nicolas Fierro, CEO of MIMIR Blockchain Solutions, will discuss how in order to protect your data and privacy, IoT applications need to embrace Blockchain technology for a new level of product security never before seen - or needed.
Leading companies, from the Global Fortune 500 to the smallest companies, are adopting hybrid cloud as the path to business advantage. Hybrid cloud depends on cloud services and on-premises infrastructure working in unison. Successful implementations require new levels of data mobility, enabled by an automated and seamless flow across on-premises and cloud resources. In his general session at 21st Cloud Expo, Greg Tevis, an IBM Storage Software Technical Strategist and Customer Solution Architec...
The use of containers by developers -- and now increasingly IT operators -- has grown from infatuation to deep and abiding love. But as with any long-term affair, the honeymoon soon leads to needing to live well together ... and maybe even getting some relationship help along the way. And so it goes with container orchestration and automation solutions, which are rapidly emerging as the means to maintain the bliss between rapid container adoption and broad container use among multiple cloud host...
Blockchain is a shared, secure record of exchange that establishes trust, accountability and transparency across business networks. Supported by the Linux Foundation's open source, open-standards based Hyperledger Project, Blockchain has the potential to improve regulatory compliance, reduce cost as well as advance trade. Are you curious about how Blockchain is built for business? In her session at 21st Cloud Expo, René Bostic, Technical VP of the IBM Cloud Unit in North America, discussed the b...
Imagine if you will, a retail floor so densely packed with sensors that they can pick up the movements of insects scurrying across a store aisle. Or a component of a piece of factory equipment so well-instrumented that its digital twin provides resolution down to the micrometer.
As DevOps methodologies expand their reach across the enterprise, organizations face the daunting challenge of adapting related cloud strategies to ensure optimal alignment, from managing complexity to ensuring proper governance. How can culture, automation, legacy apps and even budget be reexamined to enable this ongoing shift within the modern software factory? In her Day 2 Keynote at @DevOpsSummit at 21st Cloud Expo, Aruna Ravichandran, VP, DevOps Solutions Marketing, CA Technologies, was jo...
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
"Since we launched LinuxONE we learned a lot from our customers. More than anything what they responded to were some very unique security capabilities that we have," explained Mark Figley, Director of LinuxONE Offerings at IBM, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.